Mr. Stephen Van Deventer reports

PREVECEUTICAL ANNOUNCES RESULTS FROM ANNUAL GENERAL AND SPECIAL MEETING AND INCREASE TO SIZE OF NON-BROKERED PRIVATE PLACEMENT

All resolutions presented at Preveceutical Medical Inc.'s annual general and special meeting held on Friday, Oct. 10, 2025, including the following, all of which were approved:

• The election of Stephen Van Deventer, Makarand Jawadekar, Kathleen Rokita and C. Evan Ballantyne as directors of the company;
• The ratification of the appointment of Davidson & Company LLP, chartered professional accountants, as the auditor of Preveceutical for the financial year ending Dec. 31, 2024, and 2025;
• A plan of arrangement under the provisions of Division 5 of Part 9 of the Business Corporations Act (British Columbia), pursuant to which the company will distribute up to 12 million common shares of BioGene Therapeutics Inc. to the Preveceutical shareholders;
• The adoption of the Preveceutical's omnibus equity incentive plan;

The company also announces that, further to its news releases dated Aug. 5, 2025, and Sept. 5, 2025, it is increasing the size of its private placement financing. The company previously disclosed that it would issue up to 25 million units at a price of four cents per unit for gross proceeds of $1-million. The company today announces that it has increased the number of units to be issued, such that it may issue up to 30 million units at a price of four cents per unit for gross proceeds of up to $1.2-million. On Sept. 5, 2025, the company closed a first tranche of the offering, which consisted of the issuance of 16,162,500 units at a price of four cents per unit for gross proceeds of $646,500.

Each unit comprises one common share in the capital of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of six cents per warrant share for a period of 24 months from the closing of the offering, subject to an acceleration right, whereby the expiry date of the warrants may be accelerated if the daily closing price of the shares equals or exceeds 18 cents or greater on the Canadian Securities Exchange (CSE) (or such other recognized securities exchange on which the shares may then trade) for a minimum of 10 consecutive trading days, in which event the company may accelerate the expiry of the warrants by giving notice via news release and, in such case, all of the then unexercised warrants will expire on the 30th day after the date on which the news release is disseminated.

All securities to be issued pursuant to the offering are subject to a hold period expiring four months and one day after closing of the offering, in accordance with applicable securities laws.

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.